From: Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
Response
No. of patients
Percent
Complete response
-
Partial response
0
0%
Stable disease
4
40%
Progressive disease
Not available
2
20%
Overall response rate
Disease control rate
30%